Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    16338450 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine
Condition: Malaria
Interventions: Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049;   Biological: Engerix™-B;   Biological: Hiberix®;   Biological: Prevnar™;   Drug: sulfadoxine-pyrimethamine;   Drug: amodiaquine
2 Completed A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
Condition: Malaria
Intervention: Biological: RTS,S/AS02A

Indicates status has not been verified in more than two years